SCHEMBL7910656

SCHEMBL7910656

CCC(NC(=O)C1(c2ccc(F)cc2)CCN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CC1)c1ccncc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.42
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
SLC6A7 Q99884 1/20 0.41
CYP2D6 P10635 3/20 0.40
ALDH1A1 P00352 1/20 0.40
USP2 O75604 3/20 0.39
LSS P48449 2/20 0.39
CYP2C19 P33261 2/20 0.38
MAPK1 P28482 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD11B1 P28845 1/20 0.38
RORC P51449 1/20 0.38
HTR2B P41595 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378802 0.89 SLC6A9 (0.47) SMN1; SMN2SLC6A7HSD11B1
SCHEMBL7914036 0.85 SLC6A7 (0.45) KDM4EGAASMN1; SMN2SLC6A7ALDH1A1
SCHEMBL7900391 0.84 TACR1 (0.43) POLBSLC6A7HSD11B1PTPN1
SCHEMBL7910338 0.82 TACR1 (0.47) SLC6A7MAPK1HSD11B1
SCHEMBL378790 0.82 TACR1 (0.47) SLC6A7MAPK1HSD11B1
SCHEMBL13092254 0.80 KIT (0.44) POLBSLC6A7ALDH1A1HSD11B1PTPN1
SCHEMBL7908350 0.79 HSD11B1 (0.46) POLBSLC6A7HSD11B1PTPN1
SCHEMBL7908251 0.79 MAPT (0.42) CYP3A4POLBSLC6A7HSD11B1PTPN1
SCHEMBL7900653 0.77 PTPN1 (0.42) POLBSLC6A7HSD11B1PTPN1
SCHEMBL378786 0.76 MEN1 (0.46) POLBSLC6A7MAPK1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 CYP3A4 1349/4885POLB 2329/4885KDM4E 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.